Clicky

BEYOND AIR INC. DL-0001(48L)

Description: Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.


Keywords: Biopharmaceutical Solid Tumors Orphan Drug Nitrogen Cycle Bacteriology Gaseous Signaling Molecules Autism Spectrum Disorder Nitric Oxide Community Acquired Pneumonia Nontuberculous Mycobacteria Bronchiolitis Hebrew University Of Jerusalem

Home Page: www.beyondair.net

900 Stewart Avenue
Garden City, NY 11530
United States
Phone: 516 665 8200


Officers

Name Title
Mr. Steven Adam Lisi CEO & Chairman of the Board
Mr. Michael A. Gaul Chief Operating Officer
Mr. Amir Avniel Chief Executive Officer of NeuroNOS
Mr. Douglas Quinton Larson CFO, Principal Financial Officer & Principal Accounting Officer
Edward Barger Head of Investor Relations
Dr. Andrew R. Colin M.D. Senior Medical Director Global Clinical Leadership & Member of Scientific Advisory Board
Mr. David R. Webster Chief Commercial Officer
Dr. John Jett Ph.D. Head of Research & Clinical Development
Mr. Adam Newman Corporate Secretary

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.2551
Price-to-Sales TTM: 19.0955
IPO Date:
Fiscal Year End: March
Full Time Employees: 107
Back to stocks